Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
For patients with diabetes specifically, GLP-1s improve glycemic control by enhancing glucose-dependent insulin secretion and reducing glucagon secretion
Efficacy and safety of a single-pill combination of vildagliptin and metformin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial
PeptiLab products are not approved by Health Canada or the FDA for human use
Factors such as overall health, body mass index (BMI), existing health conditions, and past weight loss attempts are taken into account
Other ingredients De-ionized water, vegetable glycerin, malic acid, citric acid, natural flavors, potassium sorbate (as preservative) and lemon (citrus limon) oil
In an additional, 30-week placebo-controlled, study of patients with type 2 diabetes inadequately controlled with metformin comparing the maintenance of sitagliptin 100 mg versus withdrawal of sitagliptin when initiating basal insulin therapy, the event rate and incidence of documented symptomatic hypoglycemia (blood glucose measurement 70 mg/dL) did not differ between the sitagliptin and placebo groups
US$ 23.48
US$ 29.41
US$ 21.37
US$ 29.53
US$ 29.47
US$ 23.63
US$ 20.05
US$ 26.36
US$ 29.49
US$ 24.26
